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In the repore in which Astwood described the use of thiouracil for
the treatment of human thyrotoxicosis he was fortunately able to in-
dicate the most serious hazard which the administration of this drug
entails, that of agranulocytosis. A great volume of work has confirmed
both theeffectofthiouracil on thyroid hyperfunction and its occasionally
toxic effect on the bone marrow. Since this idiosyncratic reaction has
constituted the main obstacle to the universal use of the drug, search has
been made for agents which would prevent the occurrence of gran-
ulocytopenia, or rapidly abolish it when it occurred.
Prolonged administration of thiourea to rats was shown by Gold-
smith et al.7 to produce a neutropenia which could be prevented by the
simultaneous use of solubilized liver; the active agent in this liver
fraction was thought to be folic acid.7
Vilter, Schiro, and Spies1' observed that intravenous injections of
pyridoxine were followed by an increase in elements of the granulocytic
series in the blood. Pyridoxine was reported by Cantor and Scott3'4
to have a beneficial effect in human agranulocytosis. This view has
been supported by the more recent work of Fishberg and Vorzimer.6
Menten and Graff8 have described a favorable response in the gran-
ulocyte count in sulfonamide-induced granulocytopenia in children
following treatment with L. casei factor in conjunction with pyridoxine
hydrochloride.
On the other hand, Van Winkle et al."0 on the basis of an analysis
of several series totaling more than 5000 clinical cases, stated that
"there is no satisfactory evidence that pantothenic acid, pyridoxine,
folic acid, vitamins or pentnucleotide influence the outcome of this
disease or aid in preventing such reactions. The most important factor
in the control of granulocytopenia resulting from thiouracil therapy
* From the Department of Medicine, College of Physicians and Surgeons, Columbia
University, and the Department of Anatomy, College of Dentistry, New York University.
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appears to be discontinuance of therapy at the earliest sign of this com-
plication and promptinstitution ofvigorous treatment" (i.e., penicillin).
The clinical note of Newman and Jones' (which appeared while
this manuscript was being prepared) clearly demonstrates that even as
much as 30 mg. of crystalline folic acid per day is incapable of prevent-
ing the agranulocytosis which may be caused by thiouracil.
Careful study of case reports on patients with agranulocytosis re-
veals a wide variation in the course of the disease after withdrawal of
the inciting drug. A substance possessing curative powers for this con-
dition should, ideally, be able to exert them in the continuing presence
of the drug. Since such an experiment is too hazardous to perform on
human subjects, it is felt that its results on another primate are of
interest.
Procedure andresults
Thiouracil* was administered in relatively large doses for several
months to a group of adult rhesus monkeys.' The problem of determin-
ing the "normal" blood count in monkeys has been fully discussed by
Crafts,0 who always found more than 5000 neutrophiles per cu.mm.
Using his criteria, two animals weighing 4750 gm. and 4530 gm.,
respectively, were discovered to have developed a really significant
granulocytopenia. When this study was begun, the animals had been
receiving an average of 0.15 gm. of thiouracil per kg. of body weight
per day for more than 110 days.
During the following eight weeks, white blood and differential
counts were performed weekly on blood drawn directly from the
popliteal vein. At the end of this period, without altering the thiouracil
regimen, each animal was given an intravenous injection of 100 mg. of
pyridoxine on each of five successive days and a sixth injection on the
seventhday. White blood anddifferential counts were madeimmediately
prior to each injection and two and four days after the last injection.
From the results presented in the table it is evident that the blood
picture was not significantly altered.
* We are indebted to Dr. B. W. Carey and Dr. Stanton W. Hardy of Lederle Labo-
ratories for generous supplies of thiouracil (Deracil), folic acid' and pyridoxine
hydrochloride.
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MONKEY A B A B A B A B A B AB A B
DAe TotalWBC/mm.s% Nutro. % Bos. % aso. %Lympho. % Mono. ToalN*uro./mm.'
15-1244 6300 6500 18 22 0 0 0 0 81 78 1 0 1134 1430
21-12-44 7100 6300 34 33 5 0 0 0 55 63 6 4 2414 2079
28-12-44 6200 4200 23 17 0 0 0 0 74 80 3 3 1426 714
5-145 8200 6800 18 24 0 0 0 0 78 71 4 5 1476 1632
12-145 8000 4300 47 19 0 0 0 0 44 79 9 2 3660 817
18-1-45 6900 4500 22 13 0 0 0 0 78 84 0 3 1518 585
25-1-45 6800 5300 23 12 0 0 0 0 72 87 5 1 1564 636
30-1-45 5900 4500 31 24 0 0 0 0 65 74 4 2 1829 1080
30-1-45 Intravenous daily injections of 100 mg. of pyridoxine begun
31-1-45 7200 4300 35 22 0 0 0 0 60 74 5 4 2520 946
1-2-45 6800 3600 27 18 0 0 0 0 70 73 3 9 1836 648
2-2-45 5900 3500 28 9 0 0 .0 0 72 85 0 6 1652 315
3- 245 8100 6000 32 14 0 0 0 1 67 77 1 8 2592 840
5-245 6400 5000 31 19 0 0 0 0 66 80 3 1 1984 950
6- 2-45 Pyridoxine administration discontinued
7-2-45 5500 6100 24 21 2 0 0 0 70 71 4 8 1320 1381
9-2-45 7300 4600 15 18 0 0 0 0 85 77 0 5 1095 828
15-2-45 6500 6400 30 27 2 0 0 0 66 68 2 5 1950 1828
23- 2-45 6100 8400 32 37 0 0 0 0 66 50 2 13 1952 3408
2-3-45 6000 9450 16 40 0 0 0 1 80 57 4 2 960 3780
9-345 6300 5000 27 17 1 0 0 0 67 72 511 1701 850
12- 3-45 Oral administration of folic acid - 1.8mg. o.d. begun
14-3-45 8400 9450 20 32 1 0 0 0 '78 64 1 2 1680 3024
16-3-45 8200 7800 23 19 0 1 0 0 73 76 4 4 1886 1482
20-3-45 7800 6500 40 30 0 0 0 0 56 66 4 4 3120 1950
22-3-45 7800 5500 27 18 0 0 1 0 70 70 212 2106 990
24- 3-45 Folic acid administration discontinued
27- 3-45 8600 7800 20 18 1 2 1 0 75 73 3 7 1720 1404
30- 3-45 8300 5700 25 30 0 0 0 0 72 59 311 2075 1710
3-4-45 4200 4800 26 17 0 4 0 0 70 68 411 1092 816
10-4-45 5300 4800 34 17 012 0 0 60 70 6 1 1802 816
Five weeks later, after weekly determinations of the blood picture
during the interim, each animal wasgiven1.8 mg. of folic acid (L. casei
factor) by mouth on 12 of 13 days. The folic acid was administered in
capsules eachcontaining 0.9mg. and wasgiven along with the morning
dose of thiouracil. White and differential counts taken during and
after folic acid treatment are tabulated also, and reveal no constant
change.
Summary
Neither pyridoxine nor folic acid when given in conjunction with
thiouracil corrected the granulocytopenia produced in two monkeys by
prolonged thiouracil administration.998 YALE JOURNAL OF BIOLOGY AND MEDICINE
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